Department of Ophthalmology, 251 Hellenic Airforce General Hospital, Athens, Greece.
Ocul Immunol Inflamm. 2021 Nov 17;29(7-8):1328-1331. doi: 10.1080/09273948.2020.1745245. Epub 2020 Apr 14.
: To report a case of anterior uveitis in a patient under treatment with Cyclophosphamide / Bortezomid / Dexamethasone (CyBorD) protocol for Multiple Myeloma and concomitant use of Zoledronic acid.: Observational case report of a 50-year-old woman presenting with acute, severe, bilateral uveitis on a medical history of Multiple Myeloma, undergoing the first cycle of CyBorD protocol, including infusion with Zoledronic acid.: Continuation of therapy, with parallel treatment with topical and per os steroids led to resolution of the inflammation. Three more chemotherapy cycles were performed with the same protocol including Zoledronic acid at a lower dosage and were all, uneventful.: Our case mirrored uveitis cases with either masquerade syndrome due to Multiple Myeloma or following Zoledronic acid infusion, despite concomitant usage of Dexamethasone and Cyclophosphamide. Three consecutive rechallenges were performed without any topical prophylactic treatment and with no relapse of signs or symptoms.
: 报告一例多发性骨髓瘤患者在接受环磷酰胺/硼替佐米/地塞米松（CyBorD）方案治疗和唑来膦酸同时使用时发生前葡萄膜炎的病例。: 这是一例 50 岁女性的观察性病例报告，该患者有多发性骨髓瘤病史，正在接受第一个 CyBorD 方案周期治疗，包括唑来膦酸输注，出现急性、严重、双侧葡萄膜炎。: 继续治疗，同时局部和口服类固醇并行治疗，炎症得到缓解。随后又进行了三个周期的相同方案化疗，包括使用较低剂量的唑来膦酸，均未出现不良事件。: 我们的病例与多发性骨髓瘤引起的伪装综合征或唑来膦酸输注后发生的葡萄膜炎病例相似，尽管同时使用了地塞米松和环磷酰胺。连续进行了三次再挑战，没有进行任何局部预防性治疗，也没有出现任何体征或症状的复发。
